<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198676</url>
  </required_header>
  <id_info>
    <org_study_id>PrEP-001-104</org_study_id>
    <nct_id>NCT03198676</nct_id>
  </id_info>
  <brief_title>A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production</brief_title>
  <official_title>A Single Centre, Partially Blinded, Randomised Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prep Biopharm Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prep Biopharm Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A safety study to compare the effect of two different formulations of PrEP-001 nasal powder
      when dosed in healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single centre, randomised, partially blinded placebo-controlled repeat dose study in
      healthy male subjects to compare the effect of two different formulations of PrEP-001 nasal
      powder on nasal mucosal and serum cytokine profiles when dosed for up to five days in health
      subjects and provide additional safety and tolerability information on active PrEP-001 nasal
      powder.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Actual">May 24, 2017</completion_date>
  <primary_completion_date type="Actual">May 24, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Randomised partially blinded, partially placebo controlled, repeat dose</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in baseline in nasal mucosal secretions and serum cytokine concentrations</measure>
    <time_frame>5 days</time_frame>
    <description>Changes from baseline in nasal mucosal secretions and serum cytokine concentrations when dosed for up to 5 days with 2 different formulations of PrEP 001 Nasal Powder (ie 6.4 mg Formulation B vs 6.4 mg Formulation A)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in baseline in nasal mucosal secretions and serum cytokine concentrations</measure>
    <time_frame>5 days</time_frame>
    <description>Changes from baseline in nasal mucosal secretions and serum cytokine concentrations when dosed for up to 5 days with PrEP 001 Nasal Powder 6.4 mg Formulation B and matching placebo Formulation B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in baseline in nasal mucosal secretions and serum cytokine concentrations</measure>
    <time_frame>5 days</time_frame>
    <description>Changes from baseline in nasal mucosal secretions and serum cytokine concentrations when dosed for up to 5 days with PrEP-001 Nasal Powder (3.2 mg and 6.4 mg Formulation B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety parameters</measure>
    <time_frame>5 days</time_frame>
    <description>Assessment of the following safety variables: physical examination, safety laboratory tests, vital signs, ECGs and AEs (Formulation B vs Formulation A)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Upper Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>A - PrEP-001 6.4 mg - 0.8 mg/spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PrEP-001 Nasal Powder, 0.8 mg/spray (G-006) (Formulation A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - PrEP-001 6.4 mg - 1.6 mg/spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - PrEP-001 3.2 mg - 1.6 mg/spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PrEP-001 Placebo Nasal Powder (matching Formulation B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PrEP-001 6.4 mg</intervention_name>
    <description>6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device</description>
    <arm_group_label>A - PrEP-001 6.4 mg - 0.8 mg/spray</arm_group_label>
    <other_name>Poly-IC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PrEP-001 6.4 mg</intervention_name>
    <description>6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device</description>
    <arm_group_label>B - PrEP-001 6.4 mg - 1.6 mg/spray</arm_group_label>
    <other_name>Poly-IC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PrEP-001 3.2 mg</intervention_name>
    <description>3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device</description>
    <arm_group_label>C - PrEP-001 3.2 mg - 1.6 mg/spray</arm_group_label>
    <other_name>Poly-IC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device</description>
    <arm_group_label>D - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  Aged 18 to 65 years

          -  A body weight of &gt;50 kg and body mass index .18.0 to &lt;32.0 kg/m2

          -  Must be willing and able to communicate and participate in the whole study

          -  Must provide written informed consent

          -  Must agree to use an adequate method of contraception

        Exclusion Criteria:

          -  Subjects who have received any IMP in a clinical research study within the previous 3
             months

          -  Subjects who are study site employees, or immediate family members of a study site or
             sponsor employee

          -  Subjects who have previously been enrolled in this study

          -  History of any drug or alcohol abuse in the past 2 years

          -  Regular alcohol consumption &gt;21 units per week (1 unit = ½ pint beer, 25 mL of 40%
             spirit or a 125 mL glass of wine)

          -  Current smokers and those who have smoked within the last 12 months. A confirmed
             positive urine cotinine test at screening and admission

          -  Current smokers of e-cigarettes and nicotine replacement products and those who have
             smoked these products within the last 12 months

          -  Subject who have significant history of any tobacco use at any time (total ≥10 pack
             years history)

          -  Subjects who do not have suitable veins for multiple venepunctures as assessed by the
             investigator at screening

          -  Clinically significant abnormal biochemistry, haematology, coagulation or urinalysis
             as judged by the investigator (laboratory parameters are listed in Appendix 1)

          -  Positive drugs of abuse test result (drugs of abuse tests are listed in Appendix 1)

          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results

          -  History of clinically significant cardiovascular, renal, hepatic, chronic respiratory
             or gastrointestinal disease, or psychiatric disorder, as judged by the investigator

          -  Any chronic medical condition that could significantly reduce the ability of the
             subject to participate in the study or pose a safety concern eg unstable angina,
             uncontrolled diabetes mellitus, anaemia

          -  Any concurrent serious illness (eg diagnosis of severe depression, pulmonary
             hypertension, history of malignancy) that may interfere with a subject completing the
             study. Basal cell carcinoma within 5 years of initial diagnosis or with evidence of
             recurrence is also an exclusion

          -  Any finding in the medical history review, physical examination (including nasal exam
             with nasal speculae), screening investigations, that in the opinion of the
             investigator would compromise the subject's ability to safely complete the study

          -  Has experienced upper or lower respiratory infection (viral, fungal or bacterial) that
             resolved less than 4 weeks before Day 1

          -  Has required antibiotic treatment for a lower respiratory tract infection in the 3
             months prior to the study

          -  Subjects with a significant nasal condition eg Wegener's granulomatosis, that could
             interfere with study assessments

          -  Any significant abnormality altering the anatomy of the nose or nasopharynx on
             examination

          -  Any nasal or sinus surgery within 6 months of Day 1

          -  Any clinically significant history of epistaxis (nosebleeds) within the last 12 months
             and/or history of being hospitalised due to epistaxis on any previous occasion

          -  History or evidence of autoimmune disease or known immunodeficiency of any cause -
             with the exception of atopic eczema/atopic dermatitis. Subjects with clinically mild
             atopic eczema/atopic dermatitis may be included at the Investigator's discretion (eg
             if there is no regular use of topical steroids, no eczema in cubital fossa)

          -  Subjects with known history of Immunosuppression or known chronic viral infection

          -  Has active seasonal or perennial nasal/pharyngeal allergies at screening visit; or
             anticipates to have such symptoms during the study duration; or has had symptoms in
             the 4 weeks prior to Day 1

          -  Presence or history of clinically significant allergy requiring treatment (including
             food or drug allergy), as judged by the investigator

          -  Known allergy or adverse reaction history to formulation components

          -  Donation or loss of greater than 400 mL of blood within the previous 3 months

          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other
             than 4 g per day paracetamol) or herbal remedies in the 14 days before IMP
             administration (see Section 11.4). Exceptions may apply on a case by case basis, if
             considered not to interfere with the objectives of the study, as agreed by the PI and
             sponsor's medical monitor

          -  Failure to satisfy the investigator of fitness to participate for any other reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Litza McKenzie, MBChB BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly I-C</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

